hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06385873 id: 2024-SR-233 briefTitle: RC48 Combined With Adebrelimab and Apatinib and S-1 of the Neoadjuvant Therapy of Locally Advanced Gastric Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2028-05-01 date: 2024-04-26 date: 2024-04-26 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: This study is a prospective, open-label, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery. The study drugs include RC48, Adebrelimab, Apatinib and S-1. The purpose is to evaluate the effectiveness and safety of the combined coordinated treatment of multi-mechanism drugs for perioperative treatment of locally advanced gastric cancer with HER2 overexpression. conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: RC48 name: Adebrelimab name: Apatinib name: S-1 measure: Pathological Complete Response Rate (pCR) measure: Major Pathological Response rate (MPR) measure: R0 Resection rate measure: Disease-Free Survival (DFS） measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385860 id: GTMGS0423 briefTitle: Prediction Model for Early Biliary Stasis After Bariatric Surgery acronym: PM-EBS-BS overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2024-09 date: 2025-04 date: 2024-04-26 date: 2024-04-26 name: China-Japan Friendship Hospital class: OTHER briefSummary: Developing and validating a predictive model to estimate the risk of early biliary stasis following bariatric surgery conditions: Obesity conditions: Diabetes conditions: Gallstones conditions: Biliary Stasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 200 type: ESTIMATED measure: early biliary stasis measure: prediction model sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385847 id: GOMIMP briefTitle: To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer overallStatus: RECRUITING date: 2024-05 date: 2025-05 date: 2025-12 date: 2024-04-26 date: 2024-04-26 name: The First Affiliated Hospital of Xiamen University class: OTHER briefSummary: The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in Patients of Prostate Cancer conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Prospective, randomized, open-label, cross-over phase II trial primaryPurpose: OTHER masking: NONE count: 60 type: ESTIMATED name: Zoladex name: LY01005 measure: Patient preference sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Xiamen University status: RECRUITING city: Xiamen state: Fujian zip: 361003 country: China name: Xuegang Wang, doctor role: CONTACT phone: 15960263909 email: stefwxg@163.com lat: 24.47979 lon: 118.08187 hasResults: False
nctId: NCT06385834 id: LY2014-041-A briefTitle: The Effect of Morning vs Evening Aerobic Exercise Training on Cardiac Remodeling and Function Improvement in Patients After ST Elevation Myocardial Infarction overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2028-04-30 date: 2028-07-30 date: 2024-04-26 date: 2024-04-26 name: RenJi Hospital class: OTHER briefSummary: The aim of the study was to intervene in the Aerobic exercise time of patients with STEMI and to explore the optimal exercise time for STEMI patients conditions: ST-segment Elevation Myocardial Infarction (STEMI) studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study was divided into three groups: morning intervention group (8:00-9:00AM), evening intervention group (16:00-17:00AM) and control group primaryPurpose: TREATMENT masking: SINGLE maskingDescription: In this study, outcome measurement personnel and intervention personnel were separated during the whole process of the experiment, outcome measurement personnel did not know the grouping status, intervention personnel and rehabilitation therapists did not participate in the outcome measurement work. whoMasked: OUTCOMES_ASSESSOR count: 201 type: ESTIMATED name: Morning aerobic exercise name: Evening aerobic exercise measure: left ventricle ejection fraction measure: Oxygen consumption measure: Endothelial Function measure: Skeletal muscle and fat mass measure: Cardiac structure measure: One year major Adverse Cardiovascular Events measure: VE/VCO2-SLOPE measure: Flow-mediated dilation measure: glucose measure: Blood lipid measure: N-terminal pro-BNP sex: ALL minimumAge: 17 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385808 id: XJTU1AF-CRF-2023-XK014 briefTitle: Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-12-31 date: 2026-12-31 date: 2024-04-26 date: 2024-04-26 name: First Affiliated Hospital Xi'an Jiaotong University class: OTHER briefSummary: The primary objective of this study was to evaluate the efficacy of MTBF conditioning regimen of salvageable allo-HSCT in patients with relapsed or refractory acute myeloid leukemia. The secondary purpose of the study was to observe the safety of MTBF regimen in these patients. conditions: Relapse Leukemia conditions: Refractory Acute Myeloid Leukemia conditions: Conditioning conditions: Hematopoietic Stem Cell Transplantation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The relapsed or refractory acute myeloid leukemia patients will pretreated with the MTBF regimen prior to salvageable allogeneic hematopoietic stem cells. The one-year recurrence-free survival after transplantation of these patients and the safty of the MTBF regimen will be studied. primaryPurpose: TREATMENT masking: NONE count: 37 type: ESTIMATED name: MTBF regimen measure: Recurrence rate measure: Incidence and Severity of non-hematological adverse events (NCI CTCAE v5.0) measure: Neutrophil recovery time measure: Platelet recovery time measure: OS measure: PFS measure: aGVHD sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385795 id: NOE-PMM-201 briefTitle: A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-04-30 date: 2025-04-30 date: 2024-04-26 date: 2024-04-26 name: Noema Pharma AG class: INDUSTRY briefSummary: The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women. conditions: Menopause Syndrome conditions: Menopause conditions: Hot Flashes studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: NOE-115 measure: Withdrawals Due to Adverse Events While on NOE-115 for Any Reason measure: Number of Participants Who Experience at Least One or More Adverse Event and the Severity of the Adverse Events (AEs) measure: Weekly Mean Change in the Severity of Hot Flashes from Baseline to Week 4 measure: Weekly Mean Change in the Frequency (any severity) of Hot Flashes from Baseline to Week 4 measure: Effect of NOE-115 as Assessed by Clinical Global Impression of Severity (CGI-S) from Baseline to Week 4 sex: FEMALE minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06385782 id: 20dz1207200 briefTitle: Exploring HRV in Antarctic Overwintering Members of Asia overallStatus: COMPLETED date: 2021-03-01 date: 2022-04-01 date: 2023-09-01 date: 2024-04-26 date: 2024-04-26 name: Ya-Wei Xu class: OTHER briefSummary: Extreme changes in the Antarctic environment can cause emotional and autonomic dysfunction. In this study, volunteers from the Antarctica stations in China provided scale scores and heart rate variability (HRV) data, which were used to assess the autonomic nervous system. Enroll twenty-two members from Zhongshan Station and the Great Wall Station who are overwintering. Using the Generalized Anxiety Disorder (GAD-7) scale, the Patient Health Questionnaire-9 (PHQ-9) scale, and the SF-36 quality of life scale to evaluate the individual's general physical and mental health. Analyze HRV and other associated parameters. conditions: Heart Rate Variability studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 22 type: ACTUAL name: Antarctic environment measure: changes in HRV sex: MALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Tenth People's Hospital city: Shanghai state: Shanghai zip: 200079 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06385769 id: PamukkaleU.ftr-NYıldız-3 briefTitle: Transcutaneous Tibial Nerve Stimulation in Patients With Neurogenic Overactive Bladder After Stroke overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2026-01-31 date: 2026-02-28 date: 2024-04-26 date: 2024-04-26 name: Pamukkale University class: OTHER briefSummary: The investigators conducted a prospective, randomized, double-blind, placebo-controlled study based on the placebo technique to evaluate the efficacy of TTNS versus placebo in patients with OAB after stroke.
What are the effects of Trans Tibial Nerve Stimulation (TTNS) on incontinence-related clinical parameters and quality of life in patients with overactive bladder (OAB) after stroke compared to the placebo group? Participants (n:22) with post-stroke AAM who meet the exclusion and inclusion criteria will be divided into 2 groups using a randomization table. The first group will receive TTNS (n:11) and the second group will receive placebo TTNS (n:11). Measurements will be performed twice in total, before treatment and at the end of treatment (4th week). conditions: Urinary Bladder, Overactive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 22 type: ESTIMATED name: Transcutaneous tibial nerve stimulation (TTNS) name: Sham Transcutaneous tibial nerve stimulation (TTNS) measure: Decreased frequency of increased voiding measure: Frequency of voiding measure: The Quality of Life measure: Barthel Index for Activities of Daily Living (ADL) measure: The Overactive Bladder Symptom Score (OABSS) measure: Treatment Satisfaction Level measure: Cystometric value sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pamukkale University city: Denizli country: Turkey lat: 37.77417 lon: 29.0875 hasResults: False
nctId: NCT06385756 id: TJ-IRB202403020 briefTitle: Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-05-01 date: 2026-05-01 date: 2024-04-26 date: 2024-04-26 name: Tongji Hospital class: OTHER briefSummary: At present, there are limited data on perioperative efficacy of barbiturates at home and abroad. The purpose of this clinical trial is to observe the effects of amobarbital sodium combined with low-dose propofol on hemodynamics during induction and perioperative adverse reactions in gynecological laparoscopic surgery patients, and to provide a more reasonable, safe and comfortable anesthesia program for female patients who undergoing laparoscopic surgery.
* To record their vital signs at any point during the anaesthetic process; Serum serological indexes related to oxidative stress and inflammation were determined. The agitation during the recovery period was recorded. The incidence and severity of ponv were recorded at 2h, 2-6h, and 6-24h postoperatively, and the use of palonosetron was also recorded. conditions: Amobarbital Sodium conditions: Hemodynamics Instability studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 96 type: ESTIMATED name: Amobarbital name: Propofol measure: Mean arterial pressure (MAP) during Induction of anesthesia measure: MAP at different time points measure: Incidence of postoperative nausea and vomiting (ponv) sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06385743 id: yeditepe15 briefTitle: The Effectiveness of Neuromuscular Training-Based Exercise Program overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-17 date: 2024-07-14 date: 2024-12-30 date: 2024-04-26 date: 2024-04-26 name: Yeditepe University class: OTHER briefSummary: This randomised controlled study aimed to investigate the effectiveness of a neuromuscular training-based exercise program on pain, function, risk factors specific to shoulder injuries and performance in overhead athletes with shoulder pain.
H1: The effects of a neuromuscular training-based exercise program on pain, function, risk factors specific to shoulder injuries and performance in overhead athletes with shoulder pain are superior to the effects of "Thrower's Ten" exercise program conditions: Pain, Shoulder conditions: Sports Physical Therapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 28 type: ESTIMATED name: Neuromuscular Training-based Exercise Program name: ''Thrower's Ten'' Exercise Program measure: Pain Assessment measure: Disabilities of the Arm, Shoulder and Hand (DASH) measure: Tampa Kinesiophobia Scale measure: Hylyght Injury Prevention and Return to the Sports Screening Program ( measure: Y Balance Test- Upper Quarter measure: Closed Kinetic Chain Extremity Stability Test measure: Single Arm Seated Shot Put Test sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Yeditepe University city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06385730 id: SCE2401 briefTitle: Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS) acronym: BLESS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-05 date: 2027-05 date: 2024-04-26 date: 2024-04-26 name: Shanghai Chest Hospital class: OTHER briefSummary: The investigators will conduct a prospective phase 2 study to evaluate the efficacy and safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). conditions: Esophageal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: neoadjuvant anti-PD-1 name: neoadjuvant anti-PD-1 with LDRT measure: MPR rate measure: pCR rate measure: Adverse events and treatment-related adverse events measure: R0 resection rate measure: Objective Response rate measure: Event-free survival (EFS) measure: Overall survival (OS) measure: Correlation between potential biomarkers and tumor response sex: ALL minimumAge: 76 Years stdAges: OLDER_ADULT facility: Shanghai Chest Hospital city: Shanghai state: Shanghai zip: 200030 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06385717 id: ZhejiangU briefTitle: Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer acronym: ESCORT overallStatus: RECRUITING date: 2024-05-01 date: 2026-01-31 date: 2029-01-31 date: 2024-04-26 date: 2024-04-26 name: Second Affiliated Hospital, School of Medicine, Zhejiang University class: OTHER briefSummary: This multicenter, prospective observational cohort study has the potential to optimize individualized chemoradiotherapy regimen for early-stage esophageal cancer patients who have received endoscopic submucosal dissection. conditions: Esophagus Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: chemo-radiation measure: Incidence of toxic events measure: 3-year overall survival measure: 3-year local-regional recurrence free survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Zhejiang University School of Medicine status: RECRUITING city: Hangzhou state: Zhejiang zip: 310000 country: China name: Jing Xu, MD role: CONTACT phone: 0086-0571-87783521 email: jing_xu@zju.edu.cn lat: 30.29365 lon: 120.16142 facility: The Second Affiliated Hospital of Zhejiang University, School of Medicine status: NOT_YET_RECRUITING city: Hangzhou country: China name: Jing Xu role: CONTACT phone: 0086-0571-87783521 email: jing_xu@zju.edu.cn lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06385704 id: DMRIBFGM0420 briefTitle: Research on Changes in Intestinal Barrier Function and Gut Microbiome in Patients With Type 2 Diabetes After Duodenal Mucosal Resurfacing (DMR) acronym: DMR-IBF-GM overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-12-01 date: 2024-04-26 date: 2024-04-26 name: Wang Siqi class: OTHER name: China-Japan Friendship Hospital briefSummary: The aim of this study is to demonstrate the effects of duodenal mucosal resurfacing (DMR) on intestinal barrier function and gut microbiota when treating uncontrolled type 2 diabetes. Subjects who underwent DMR and those who did not were enrolled, and potential differences were identified by analyzing urine and fecal samples through microbiomic analysis and High Performance Liquid Chromatography（HPLC）, combined with changes in clinical data. conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 100 type: ESTIMATED name: DMR Procedure measure: Microbiome Analysis measure: High Performance Liquid Chromatography sex: ALL minimumAge: 25 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06385691 id: ET22-145 briefTitle: Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer. acronym: MyDIET overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2026-06-30 date: 2026-08-31 date: 2024-04-26 date: 2024-04-26 name: Centre Leon Berard class: OTHER briefSummary: This is a prospective, single-center, single-arm Phase II study evaluating the efficacy of the myDIET software tool in the nutritional management of patients with localized and resectable esogastric junction cancer. conditions: Gastric Cancer conditions: Oesogastric Junction Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a prospective, single-center, single-arm Phase II study. primaryPurpose: PREVENTION masking: NONE count: 60 type: ESTIMATED name: myDIET software tool measure: Proportion of patients starting adjuvant chemotherapy within 2 months measure: Adherence to the tool measure: Number of supportive care and emergency consultations initiated by the caregiver measure: Proportion of patients with malnutrition measure: Evolution of body composition in L3 section (volumes) measure: Evolution of body composition in L3 section (indexes) measure: Evolution of resting energy expenditure measure: Proportion of patient covering theoretical nutritional requirement >= 30kcal/kg/day measure: Comparison between theoretical nutritional requirement and measurement of basal metabolic rate using indirect calorimetry measure: Weight changes measure: Brachial circumference changes measure: Triceps skin fold changes measure: Initiation time for post-operative chemotherapy measure: Proportion of patient with incomplete scheme of pre operative chemotherapy measure: Proportion of patient with incomplete scheme of post operative chemotherapy measure: Proportion of patients with severe post operative complication measure: Tolerance to perioperative chemotherapy measure: Changes in food intake measure: Changes in SEFI (Easy Food Intake Score) measure: Measurement of quality of life measure: Average lengh of hospital stay measure: Recurrence free survival (RFS) measure: Overall survival (OS) measure: Adherence to the physical activity program measure: Physical activity levels measure: Assessment of muscular function by the 6-min walk test measure: Assessment of muscular function by muscular strength sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Léon Berard city: Lyon zip: 69008 country: France name: Pamela Funk-Debleds, MD role: CONTACT phone: 0469856020 phoneExt: +33 email: pamela.funk-debleds@lyon.unicancer.fr name: Clélia Coutzac, MD role: CONTACT phone: 0469856020 phoneExt: +33 email: clelia.coutzac@lyon.unicancer.fr lat: 45.74848 lon: 4.84669 hasResults: False
nctId: NCT06385678 id: HRS-4642-201 briefTitle: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-10 date: 2026-08 date: 2024-04-26 date: 2024-04-26 name: Jiangsu HengRui Medicine Co., Ltd. class: INDUSTRY briefSummary: The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation. conditions: Advanced KRAS G12D Mutant Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: HRS-4642 name: Adebrelimab name: SHR-A1921 name: Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection measure: Phase IB: Safety endpoints: adverse events (AEs). measure: Phase IB： Maximum tolerated dose (MTD) measure: Phase IB：Recommended phase 2 dose (RP2D) measure: Phase II: Overall response rate (ORR). measure: Efficacy endpoints: Overall response rate (ORR). measure: Efficacy endpoints: Duration of response (DoR). measure: Efficacy endpoints: Disease control rate (DCR). measure: Efficacy endpoints: Progression free survival (PFS). measure: Efficacy endpoints: overall survival (OS). sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai East Hospital city: Shanghai state: Shanghai zip: 200120 country: China name: Caicun Zhou, Doctor role: CONTACT phone: 13301825532 email: caicunzhoudr@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06385665 id: Xin Peng briefTitle: The Effect of Appropriate Family Companionship on the Physical and Mental Health of Patients With Advanced Breast Cancer overallStatus: RECRUITING date: 2024-04-22 date: 2024-04-22 date: 2024-12-31 date: 2024-04-26 date: 2024-04-26 name: Xin Peng class: OTHER briefSummary: The goal of this clinical trial is to learn about companionship needs in breast cancer patients who are pathologically or cytologically diagnosed as cancer, are alive with the tumor, and have TNM clinical stage IV. The main questions it aims to answer are: